ABSTRACT

Parkinson's accounts for the second most common neurodegenerative disease with about 10 million cases affected by it, out of which most cases are familial. Eighteen years of genetic research in Parkinsonism has led to the identification of several genetic risk factors that have contributed to this disease. Hence, targeting such genes for therapeutic intervention can be a good strategy in Parkinson's treatment. Mutations in such dominantly or recessively inherited genes have led to its conversion into monogenic forms that conclusively have been shown to cause hereditary-based parkinsonism. Four such genes like SNCA, LRRK2, PRKN, and PINK 1 have been extensively discussed in this review since their contribution towards the pathology of Parkinson's is more clinically significant than the other genes. The onset of this disease usually starts after the age of 60, but in some cases, early symptoms of the disease can also be observed in patients. Thus, strategizing treatment plans is a major driving force behind Parkinson's research. This review briefly summarizes the function of the genes and their role in the pathogenesis of the disease as well as the clinical manifestations and genetic components of Parkinson's disease. This article will help researchers on pursuing ground-breaking research towards the management of Parkinson's disease. Keywords: LRRK2, Parkinson's disease, PINK1, PRKN, SNCA
Publication date: 01/12/2022

https://ijbpas.com/pdf/2022/December/MS_IJBPAS_2022_6646.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.12.6646